Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD

Patients with advanced-stage Hodgkin lymphoma treated with ABVD who have a positive interim FDG-PET (iPET) have a poor prognosis. Escalation to BEACOPP has been shown to improve progression-free survival (PFS). However, randomized trials are lacking to determine the best strategy for intensification. We report on A-AVD escalation treatment outcomes for 15 iPET-positive patients post-ABVD. Overall response and complete response rates were 80% and 60%, respectively. Four patients underwent salvage therapy followed by autologous stem cell transplantation. At a median 17-month follow-up, all patients are alive, 87% in complete remission, and 1-year PFS was 57.8%. For patients ineligible for BEACOPP due to age, comorbidities, or preference, A-AVD escalation may be a viable alternative.

Authors

Institutions

Publication Details

Journal
Hematological Oncology
Published
2024-08-12
DOI
https://doi.org/10.1002/hon.3299
Citations
4
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.70
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD

Antonio M. Gutierrez, Xavier Setoaín, Carmen Martı́nez, Esther Carcelero et al.
4 citations
Hematological Oncology
Lymphoma Diagnosis and Treatment
1.70
article

Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD

Antonio M. Gutierrez, Xavier Setoaín, Carmen Martı́nez, Esther Carcelero, Jordi Esteve, Josep M. Martí-Tutusaus, Sónia Rodríguez, Pablo Mozas, Esther Sancho, Gabriela Antelo, Laura Magnano, Francesc Fernández‐Avilés
article en
4 citations

Abstract

Patients with advanced-stage Hodgkin lymphoma treated with ABVD who have a positive interim FDG-PET (iPET) have a poor prognosis. Escalation to BEACOPP has been shown to improve progression-free survival (PFS). However, randomized trials are lacking to determine the best strategy for intensification. We report on A-AVD escalation treatment outcomes for 15 iPET-positive patients post-ABVD. Overall response and complete response rates were 80% and 60%, respectively. Four patients underwent salvage therapy followed by autologous stem cell transplantation. At a median 17-month follow-up, all patients are alive, 87% in complete remission, and 1-year PFS was 57.8%. For patients ineligible for BEACOPP due to age, comorbidities, or preference, A-AVD escalation may be a viable alternative.

Hematological OncologyVol. 42(5)
University Hospital Mútua de Terrassa (ES), Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (ES), Hospital General de Granollers (ES), Hospital Clínic de Barcelona (ES), Hospital Universitario Son Espases (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
Openalex Percentile: Top 16%
Lymphoma Diagnosis and Treatment
1.70
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.